Welcome to our dedicated page for Niagen Bioscience news (Ticker: NAGE), a resource for investors and traders seeking the latest updates and insights on Niagen Bioscience stock.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience (NASDAQ: NAGE) will report third quarter 2025 financial results for the period ended September 30, 2025, after market close on Tuesday, November 4, 2025. Management will host an investor conference call on Tuesday, November 4, 2025 at 4:30 p.m. ET to discuss the results and provide a general business update.
Call participants should dial in at least 10 minutes early. Toll-free dial-in: +1 888 596 4144 with Conference ID 8584242. A live webcast will be available on the company investor relations site and a replay will be available from 7:30 p.m. ET on November 4, 2025 through 11:59 p.m. ET on November 11, 2025 (toll-free replay +1 800 770 2030, Replay ID 8584242).
Summary not available.
Niagen Bioscience (NASDAQ: NAGE) has expanded the availability of its pharmaceutical-grade Niagen Plus™ products to over 900 clinics nationwide, including more than 50 iCRYO locations. The company's Niagen IV and injections, which boost NAD+ levels, demonstrated superior performance compared to traditional NAD+ IV therapy in clinical studies, featuring 75% shorter infusion times and a 20% increase in whole blood NAD+ levels.
The partnership with iCRYO aligns with both companies' focus on preventative health solutions and longevity. Niagen's nicotinamide riboside (NR) is clinically validated as the most efficient NAD+ booster, addressing the natural decline of NAD+ levels associated with aging and stress. The treatment supports cellular function, metabolic health, and overall well-being.
Niagen Bioscience (NASDAQ: NAGE) has launched an enhanced version of AboutNAD®, a comprehensive online platform dedicated to NAD+ science and research. The website serves as a centralized educational resource focusing on nicotinamide riboside (NR), featuring peer-reviewed studies and scientific advancements in NAD+ biology.
The platform includes a categorized research database, advanced search functionality, expert perspectives, and scientific newsletters. Content is structured around three core principles: evidence-based research, accessibility, and community orientation, aiming to bridge the gap between scientific research and public understanding of NAD+ biology and its role in healthy aging.
["Creation of a centralized, authoritative resource for NAD+ research", "Platform focuses on peer-reviewed, evidence-based content", "Enhanced user experience with categorized database and advanced search features"]Niagen Bioscience (NASDAQ:NAGE) reported strong Q2 2025 financial results, with total net sales increasing 37% to $31.1 million. The company's flagship product Tru Niagen® achieved sales of $22.7 million, growing 22%, while Niagen® ingredient sales surged 135% to $7.4 million. The company reported net income of $3.6 million ($0.05 per share) and improved gross margin by 480 basis points to 65.0%.
Key operational highlights include completing patient dosing in the Phase III NOPARK trial for Parkinson's disease, securing an exclusive license agreement with Haukeland University Hospital, and expanding Niagen Plus products to over 800 wellness clinics. The company raised its full-year 2025 revenue growth outlook to 22-27% from the previous 20-25%.
Niagen Bioscience (NASDAQ: NAGE) has published groundbreaking clinical study results in Aging Cell, demonstrating the efficacy of their patented nicotinamide riboside (NR) ingredient, Niagen®, in treating Werner syndrome (WS), a rare genetic aging disorder. The 52-week randomized, double-blind, placebo-controlled crossover trial showed that daily 1,000mg Niagen supplementation increased NAD+ levels by approximately 140% and improved cardiovascular and skin health markers.
Key findings include improved arterial stiffness, beneficial changes in HDL particles, and reduced skin ulcer size. The study involved nine individuals with WS, with no moderate or severe adverse events reported. This research expands Niagen's rare disease portfolio, which includes promising results in Ataxia Telangiectasia (AT), where the FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation.
Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, announced its participation in Canaccord Genuity's 45th Annual Growth Conference from August 12-14, 2024, in Boston.
CEO Rob Fried and CFO Ozan Pamir will participate in a fireside chat on August 12 at 12:00 PM ET. The executives will also conduct one-on-one meetings with institutional investors during the conference. The presentation will be available via webcast, with a replay accessible on the company's investor relations website.
Niagen Bioscience (NASDAQ: NAGE), a company focused on NAD+ and healthy aging science, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025.
The company will release its Q2 2025 financial results after market close, followed by an investor conference call at 4:30 p.m. ET. Management will discuss the financial performance and provide a business update during the call, which will be accessible via webcast through the company's investor relations website.
Niagen Bioscience (NASDAQ: NAGE) has announced the debut of its flagship products at Equinox Hotel New York. Tru Niagen®, the leading NAD+ supplement in the US, will be available as an in-room amenity, while Niagen IV will be offered at the hotel's spa through NutriDrip.
The partnership aims to provide hotel guests with science-backed cellular health benefits through Niagen® (patented nicotinamide riboside), which supports cellular energy production and DNA repair. The collaboration with Equinox Hotel and NutriDrip represents Niagen Bioscience's strategy to expand consumer access and capture new market opportunities.
Niagen Bioscience (NASDAQ: NAGE) has secured a worldwide exclusive commercial license agreement with Haukeland University Hospital in Bergen, Norway, to develop and commercialize its NAD+ precursor Niagen® (nicotinamide riboside) as a potential Parkinson's Disease therapy.
The agreement grants exclusive rights to proprietary intellectual property and data, including results from the NOPARK trial - a phase III clinical study involving 400 early-stage Parkinson's patients across 12 Norwegian sites. The 52-week study, completed in June 2025, evaluated 500mg of Niagen twice daily versus placebo.
This collaboration builds on previous research partnerships dating back to March 2018, which have resulted in over 300 research collaborations and more than 35 peer-reviewed clinical studies. The company has established a new subsidiary to transition from supplement science to regulated drug development.